# South Texas Accelerated Research Therapeutics

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/south-texas-accelerated-research-therapeutics/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 71 |
| Citations | 119,176 |
| City | San Antonio |
| Country | US |
| Description | South Texas Accelerated Research Therapeutics is a research organisation in San Antonio, US. OpenAlex records 1,533 works and 119,176 citations for it. 224 researchers list it as their most recent affiliation. |
| Homepage | http://startthecure.com/ |
| OpenAlex ID | https://openalex.org/I4210119066 |
| Region | Texas |
| Researchers | 224 |
| ROR ID | https://ror.org/01scs7915 |
| Type | facility |
| Works | 1,533 |

## University collaborators

- [University of California, Los Angeles](https://scholariq.org/institutions/university-of-california-los-angeles/)

## University papers

- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors](https://scholariq.org/papers/efficacy-and-safety-of-abemaciclib-an-inhibitor-of-cdk4-and-cdk6-for-patients/)
- [Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors](https://scholariq.org/papers/phase-i-study-of-ro4929097-a-gamma-secretase-inhibitor-of-notch-signaling-in/)
- [First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas](https://scholariq.org/papers/first-in-human-phase-i-study-of-copanlisib-bay-80-6946-an-intravenous-pan-class/)
- [First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors](https://scholariq.org/papers/first-in-human-study-of-amg-820-a-monoclonal-anti-colony-stimulating-factor-1/)
- [MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer](https://scholariq.org/papers/mrtx1719-is-an-mta-cooperative-prmt5-inhibitor-that-exhibits-synthetic-lethality/)
- [Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study](https://scholariq.org/papers/datopotamab-deruxtecan-in-advanced-or-metastatic-hr-her2-and-triple-negative/)

## University top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Research and Treatments](https://scholariq.org/topics/cancer-research-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.